Travere Therapeutics

(NASDAQ) TVTX

Current Price$45.00

Market Cap$4.15B

Since IPO (2012)+757%

5 Year+87%

1 Year+112%

1 Month+48%

Travere Therapeutics Financials at a Glance

Market Cap

$4.15B

Revenue (TTM)

$490.73M

Net Income (TTM)

$50.26M

EPS (TTM)

$-0.60

P/E Ratio

-74.48

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$45.00

Volume

69,246

Open

$43.93

Price

$45.00

Volume

69,246

Open

$43.93

Previous Close

$45.00

Daily Range

$43.93 - $45.42

52-Week Range

$13.88 - $45.43

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$45.00

Volume

69,246

Open

$43.93

Previous Close

$45.00

Daily Range

$43.93 - $45.42

52-Week Range

$13.88 - $45.43

TVTX News

Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started?

Jonathan PoncianoApr 20, 2026

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?

Robert IzquierdoJan 25, 2026

Person seated at a desk with two PC monitors holding head in hands.

Page 1

TVTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Travere Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

497

CEO

Eric M. Dube, PhD

Website

www.travere.com

Headquarters

San Diego, CA 92130, US

TVTX Financials

Key Financial Metrics (TTM)

Gross Margin

94%

Operating Margin

-13%

Net Income Margin

-10%

Return on Equity

-58%

Return on Capital

-14%

Return on Assets

-8%

Earnings Yield

-1.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.15B

Shares Outstanding

92.37M

Volume

69.25K

Avg. Volume

1.86M

Financials (TTM)

Gross Profit

$419.65M

Operating Income

$62.82M

EBITDA

$22.22M

Operating Cash Flow

$37.78M

Capital Expenditure

$0.00

Free Cash Flow

$37.78M

Cash & ST Invst.

$322.80M

Total Debt

$328.73M

Travere Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$129.69M

+73.4%

Gross Profit

$109.00M

+50.9%

Gross Margin

84.05%

N/A

Market Cap

$4.15B

N/A

Market Cap/Employee

$10.77M

N/A

Employees

385

N/A

Net Income

$21.99M

+63.5%

EBITDA

$632.00K

+98.6%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$17.07M

+44.7%

Accounts Receivable

$81.43M

+200.3%

Inventory

$5.88M

-5.2%

Long Term Debt

$333.99M

+2.0%

Short Term Debt

$5.88M

-92.1%

Return on Assets

-8.30%

N/A

Return on Invested Capital

-14.11%

N/A

Free Cash Flow

$61.05M

+234.8%

Operating Cash Flow

$60.68M

+269.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

XENEXenon Pharmaceuticals Inc.

XENEXenon Pharmaceuticals Inc.$57.40+2.26%

LEGNLegend Biotech Corporation

LEGNLegend Biotech Corporation$26.50+12.34%

APGEApogee Therapeutics, Inc.

APGEApogee Therapeutics, Inc.$83.55+3.47%

TARSTarsus Pharmaceuticals, Inc.

TARSTarsus Pharmaceuticals, Inc.$64.57+1.49%

IRONDisc Medicine, Inc.

IRONDisc Medicine, Inc.$67.64+1.09%

CGONCG Oncology, Inc. Common stock

CGONCG Oncology, Inc. Common stock$67.70+2.16%

RAREUltragenyx Pharmaceutical Inc.

RAREUltragenyx Pharmaceutical Inc.$24.81+0.16%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$198.52+0.00%

INTCIntel

INTCIntel$95.70-0.04%

PLTRPalantir Technologies

PLTRPalantir Technologies$145.90+0.01%

AMZNAmazon

AMZNAmazon$271.92+0.01%

AAPLApple

AAPLApple$276.80-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.24-0.01%

XNDUXanadu Quantum Technologies

XNDUXanadu Quantum Technologies$13.89-0.62%

Questions About TVTX

What is the current price of Travere Therapeutics?

Travere Therapeutics is trading at $45.00 per share.

What is the 52-week range for Travere Therapeutics?

Over the past 52 weeks, Travere Therapeutics has traded between $13.88 and $45.43.

How much debt does Travere Therapeutics have?

As of the most recent reporting period, Travere Therapeutics reported total debt of $328.73M.

How much cash does Travere Therapeutics have on hand?

Travere Therapeutics reported $93.03M in cash and cash equivalents in its most recent financial results.

What is Travere Therapeutics’s dividend yield?

Travere Therapeutics does not currently have a dividend yield.

Travere Therapeutics

Travere Therapeutics Financials at a Glance

TVTX News

Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started?

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?

Why Travere Therapeutics Stock Got Trounced on Tuesday

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Why Shares of Travere Therapeutics Are Slumping Thursday

Could an FDA Approval Send This Stock Flying?

Why Travere Therapeutics Stock Bolted Higher This Week

TVTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Travere Therapeutics

TVTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Travere Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TVTX

What is the current price of Travere Therapeutics?

What is the 52-week range for Travere Therapeutics?

How much debt does Travere Therapeutics have?

How much cash does Travere Therapeutics have on hand?

What is Travere Therapeutics’s dividend yield?

Premium Investing Services